Exscientia

Recursion received FDA clearance for a Phase 1/2 trial of REC-1245, targeting solid tumors and lymphoma, set to start in Q4 2024. The drug, developed using AI, targets RBM39, potentially addressing a significant unmet need. Recursion's platform combines experimental and computational approaches for drug discovery. The company, listed on NASDAQ: RXRX, is based in Salt Lake City and part of the Utah life sciences collective, BioHive.

AI-based Clinical Trials Solution Provider Market to reach USD 7.64 billion by 2032 with a CAGR of 22.0%, driven by AI's role in trial design, patient recruitment, data analysis, and regulation, aiming to enhance speed, reduce costs, and improve data reliability.

Cathie Wood's Ark Innovation ETF added Intellia Therapeutics (gene-editing) and Recursion Pharmaceuticals (AI-driven drug development) to its portfolio, highlighting their potential despite risks.

Generative AI in drug discovery promises to accelerate the process, but faces challenges like data quality, model transparency, and industry collaboration. While early successes exist, the technology is not yet ready to replace traditional methods entirely.

AI in healthcare promises faster, more accurate diagnoses, personalized treatment plans, accelerated drug discovery, streamlined administrative tasks, outbreak prediction, and enhanced telehealth. Challenges include ethical concerns and regulatory frameworks.

The Global Biotechnology Market, valued at USD 1,094.6 Billion in 2024, is projected to reach USD 2772.7 Billion by 2032, with a CAGR of 14.2%. The market report includes detailed analysis, key players, and segments such as applications and technologies, with regional assessments covering North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.

Recursion announced Phase 2 SYCAMORE trial results for REC-994, a CCM treatment, showing safety and promising MRI-based efficacy at the highest dose. The study, involving 62 participants, met primary safety endpoints but lacked significant patient-reported improvements. Recursion plans further FDA discussions and data publication. CCM affects 360,000 in the US and EU5, with Recursion leveraging its Recursion OS for drug development.

The global AI in pharma and biotech market, valued at US$ 1.8 billion in 2023, is projected to reach US$ 13.1 billion by 2034, growing at a CAGR of 18.8%. AI transforms drug discovery by speeding up the process, reducing costs, and enhancing precision medicine through advanced data analytics and machine learning. North America leads in AI-driven biotech, with significant contributions from research institutions and tech companies.